AngioDynamics (NASDAQ:ANGO) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Several other research firms have also recently weighed in on ANGO. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of AngioDynamics in a report on Wednesday, July 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Saturday, September 27th. Lake Street Capital assumed coverage on AngioDynamics in a report on Wednesday, July 16th. They set a “buy” rating and a $24.00 price target for the company. Finally, Canaccord Genuity Group lifted their price target on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Trading Down 3.3%

Shares of NASDAQ ANGO opened at $11.26 on Friday. AngioDynamics has a 12 month low of $5.83 and a 12 month high of $13.50. The stock has a 50 day moving average of $9.98 and a 200-day moving average of $9.77. The company has a market capitalization of $463.91 million, a P/E ratio of -14.44 and a beta of 0.78.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million during the quarter, compared to the consensus estimate of $72.69 million. During the same period in the previous year, the company posted ($0.11) EPS. The firm’s revenue for the quarter was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Analysts predict that AngioDynamics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANGO. GAMMA Investing LLC raised its stake in AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock worth $130,000 after buying an additional 12,891 shares during the period. Acuitas Investments LLC raised its stake in AngioDynamics by 9.7% during the 1st quarter. Acuitas Investments LLC now owns 442,230 shares of the medical instruments supplier’s stock worth $4,153,000 after buying an additional 38,950 shares during the period. Principal Financial Group Inc. raised its stake in AngioDynamics by 25.1% during the 1st quarter. Principal Financial Group Inc. now owns 120,008 shares of the medical instruments supplier’s stock worth $1,127,000 after buying an additional 24,047 shares during the period. Cornerstone Investment Partners LLC acquired a new position in AngioDynamics during the 1st quarter worth approximately $169,000. Finally, Cerity Partners LLC raised its stake in AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 2,333 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.